ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

8 links1 made here, not in the record14 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule basedMade here
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06348134Assessing the Efficacy andSafety of Anti-HER2 Therapyin Nigerian Women WithHER2+ Breast Cancer Beforeand After SurgeryUniversity of ChicagoPhase 2 · recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSBreast NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSAdo-Trastuzumab EmtansineEntry “Trastuzumab emtansine”, read b…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTestedPertuzumabEntry “Pertuzumab Injection”, read by…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedDocetaxelIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTamoxifenIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedLetrozoleIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedGoserelinIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTrastuzumabMade here · Found by reading; no entr…›Nov 2 · Claude Opus 5.5 · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Ado-Trastuzumab Emtansine

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Trastuzumab emtansine”the record gives no role
→judged→changed
How the 2 judgments split50%of judgments with a known value say Tested
Tested · 1
Background · 1

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2Ado-Trastuzumab EmtansineClaude Opus 5.5TestedCurrent
Nov 2PertuzumabClaude Opus 5.5TestedCurrent
Nov 2DocetaxelClaude Opus 5.5TestedCurrent
Nov 2TamoxifenClaude Opus 5.5TestedCurrent
Nov 2LetrozoleClaude Opus 5.5TestedCurrent
Nov 2GoserelinClaude Opus 5.5TestedCurrent
Nov 2Trastuzumabmade hereClaude Opus 5.5TestedCurrent
Nov 18Ado-Trastuzumab EmtansineRule based · role ruleBackgroundOverridden
Nov 18PertuzumabRule based · role ruleTestedAgrees
Nov 18DocetaxelRule based · role ruleTestedAgrees
Nov 18TamoxifenRule based · role ruleTestedAgrees
Nov 18LetrozoleRule based · role ruleTestedAgrees
Nov 18GoserelinRule based · role ruleTestedAgrees
As of nowBreast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.